Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Calibrant Biosystems has started research collaboration with the Cleveland Clinic to identify novel drug targets for primary brain cancer using Calibrant's gemini proteomics platform.
Subscribe to our email newsletter
As part of the partnership, Calibrant will identify protein networks and novel therapeutic targets involved in the progression of the most common and aggressive primary brain cancer, glioblastoma multiforme (GBM).
Brian Balgley, chief technology officer of Calibrant, said: “Our collaboration represents another important cancer drug program for Calibrant. The study reflects Calibrant’s ability to apply the gemini platform to targeted discovery from microdissected cell populations for the effective identification of disease-relevant pathways and drug targets.”